Literature DB >> 26662184

Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level.

Sandra Feijóo-Bandín1, Diego Rodríguez-Penas2, Vanessa García-Rúa2, Ana Mosquera-Leal2, José Ramón González-Juanatey2, Francisca Lago2.   

Abstract

Nesfatin-1 is a new energy-regulating peptide widely expressed at both central and peripheral tissues with pleiotropic effects. In the last years, the study of nesfatin-1 actions and its possible implication in the development of different diseases has created a great interest among the scientific community. In this review, we will summarize nesfatin-1 main functions, focusing on its cardiovascular implications.

Entities:  

Keywords:  Cardiovascular; Energy homeostasis; Metabolism; Nesfatin-1; Viability

Mesh：

Substances：

Year:  2015        PMID： 26662184     DOI： 10.1007/s12020-015-0819-z

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


  164 in total

1.  The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist.

Authors:  Gina L C Yosten; Willis K Samson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-03-24       Impact factor: 3.619

2.  The effect of Nesfatin-1 on heart L-type Ca²⁺ channel α1c subunit in rats subjected to chronic restraint stress.

Authors:  C Ayada; G Turgut; S Turgut
Journal:  Bratisl Lek Listy       Date:  2015       Impact factor: 1.278

3.  Nesfatin-1 exerts long-term effect on food intake and body temperature.

Authors:  K Könczöl; O Pintér; S Ferenczi; J Varga; K Kovács; M Palkovits; D Zelena; Z E Tóth
Journal:  Int J Obes (Lond)       Date:  2012-01-31       Impact factor: 5.095

Review 4.  The brain-adipose axis: a review of involvement of molecules.

Authors:  Hiroyuki Shimizu; Masatomo Mori
Journal:  Nutr Neurosci       Date:  2005-02       Impact factor: 4.994

5.  NUCB2/nesfatin-1 is associated with elevated scores of anxiety in female obese patients.

Authors:  Tobias Hofmann; Andreas Stengel; Anne Ahnis; Petra Buße; Ulf Elbelt; Burghard F Klapp
Journal:  Psychoneuroendocrinology       Date:  2013-06-21       Impact factor: 4.905

6.  Molecular characterisation and expression analysis of SEREX-defined antigen NUCB2 in gastric epithelium, gastritis and gastric cancer.

Authors:  Zane Kalnina; K Silina; R Bruvere; N Gabruseva; A Stengrevics; S Barnikol-Watanabe; M Leja; A Line
Journal:  Eur J Histochem       Date:  2009 Jan-Mar       Impact factor: 3.188

7.  Serum levels of the adipokines, free fatty acids, and oxidative stress markers in obese and non-obese preeclamptic patients.

Authors:  A Turgut; A Ozler; N Y Goruk; S Y Tunç; M E Sak; M S Evsen; O Evliyaoglu; T Gul
Journal:  Clin Exp Obstet Gynecol       Date:  2015       Impact factor: 0.146

8.  Nesfatin-1 in human and murine cardiomyocytes: synthesis, secretion, and mobilization of GLUT-4.

Authors:  Sandra Feijóo-Bandín; Diego Rodríguez-Penas; Vanessa García-Rúa; Ana Mosquera-Leal; Manuel Francisco Otero; Eva Pereira; José Rubio; Isabel Martínez; Luisa María Seoane; Oreste Gualillo; Manuel Calaza; Tomás García-Caballero; Manuel Portolés; Esther Roselló-Lletí; Carlos Diéguez; Miguel Rivera; José Ramón González-Juanatey; Francisca Lago
Journal:  Endocrinology       Date:  2013-09-24       Impact factor: 4.736

9.  Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism.

Authors:  Sandra Cappello; Tommaso Angelone; Bruno Tota; Pasquale Pagliaro; Claudia Penna; Raffaella Rastaldo; Angelo Corti; Gianni Losano; Maria Carmela Cerra
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-04-06       Impact factor: 4.733

10.  Long-term infusion of nesfatin-1 causes a sustained regulation of whole-body energy homeostasis of male Fischer 344 rats.

Authors:  Sima Mortazavi; Ronald Gonzalez; Rolando Ceddia; Suraj Unniappan
Journal:  Front Cell Dev Biol       Date:  2015-04-08
View more
  8 in total

Review 1.  Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome.

Authors:  Tuba Tekin; Betul Cicek; Nurefsan Konyaligil
Journal:  Eurasian J Med       Date:  2019-08-19

2.  Nesfatin-1 Levels Predict Angiographic No-Reflow in Patients with ST-Segment Elevation Myocardial Infarction.

Authors:  Serkan Sivri; Erdoğan Sökmen; Mustafa Çelik; Kenan Güçlü
Journal:  Acta Cardiol Sin       Date:  2020-07       Impact factor: 2.672

3.  SERUM NESFATIN-1 LEVEL IN HEALTHY SUBJECTS WITH WEIGHT-RELATED ABNORMALITIES AND NEWLY DIAGNOSED PATIENTS WITH TYPE 2 DIABETES MELLITUS; A CASE-CONTROL STUDY.

Authors:  S Mirakhor Samani; H Ghasemi; K Rezaei Bookani; B Shokouhi
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jan-Mar       Impact factor: 0.877

4.  The Relationship between Nesfatin-1 Levels and SYNTAX Score in Patients with Non-ST Segment Elevation Myocardial Infarction.

Authors:  Mevlüt Serdar Kuyumcu; Aliye Kuyumcu; Çağrı Yayla; Mustafa Bilal Özbay; Sefa Ünal; Burak Açar; Cemil Nural; Almila Şenat; Gülhan Samur
Journal:  Acta Cardiol Sin       Date:  2018-09       Impact factor: 2.672

5.  Nesfatin-1 protects against diabetic cardiomyopathy in the streptozotocin-induced diabetic mouse model via the p38-MAPK pathway.

Authors:  Zhanwei Fan; Jianjiang Dong; Yindong Mu; Xian Liu
Journal:  Bioengineered       Date:  2022-06       Impact factor: 6.832

Review 6.  Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Diego Rodríguez-Penas; Manuel Portolés; Esther Roselló-Lletí; Miguel Rivera; José R González-Juanatey; Francisca Lago
Journal:  Front Physiol       Date:  2017-08-18       Impact factor: 4.566

7.  The effects of Desflurane and Sevoflurane on Nesfatin-1 levels in laparoscopic Cholecystectomy: a randomized controlled trial.

Authors:  A T D Ozcan; C B Altin; S Erdogan; M Ergin; A Çiftçi; H Kara; S M Aksoy; A But
Journal:  BMC Anesthesiol       Date:  2018-02-16       Impact factor: 2.217

Review 8.  Adipokines and Inflammation: Focus on Cardiovascular Diseases.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Sandra Moraña-Fernández; Laura Anido-Varela; Estefanía Tarazón; Esther Roselló-Lletí; Manuel Portolés; Isabel Moscoso; Oreste Gualillo; José Ramón González-Juanatey; Francisca Lago
Journal:  Int J Mol Sci       Date:  2020-10-18       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.